USING INFORMATION FROM THE MICROBIOME TO IMPROVE THE EFFICIENCY OF SELECTING THERAPEUTIC OPTIONS FOR MELANOMA- A COST-EFFECTIVENESS ANALYSIS

Author(s)

Padula W1, Chen Y2, Reid N3, Tierce J4, Popper C5, Walz K5
1University of Southern California, Los Angeles, CA, USA, 2University of Virginia, Charlottesville, VA, USA, 3Monument Analytics, Baltimore, MD, USA, 4Monument Analytics, Colorado Springs, CO, USA, 5Popper and Co., Baltimor, MD, USA

Presentation Documents

OBJECTIVES : This study evaluated the cost-effectiveness of adding a gut microbiome test (GMT) to PD-L1 testing to guide treatment choice between immunotherapy and chemotherapy options in the care of patients with metastatic or unresectable melanoma.

METHODS : This study applied a decision tree model to study the cost-effectiveness of adding a gut microbiome test (GMT) to routine PD-L1 testing to guide treatment decisions for patients with metastatic or unresectable. Treatment options included immunotherapy or chemotherapy protocol. The analysis was conducted from the public perspective; the majority of patients were Medicare beneficiaries. The model’s time horizon was 32 weeks or 16 weeks depending on whether patients’ first-line treatment fails. Costs were calculated in US Dollars (USD, $) and adjusted for inflation to 2019 USD. Quality-adjusted life years (QALYs) were used to measure effectiveness. Both univariate and probabilistic sensitivity analyses were used to assess the reliability of the deterministic results and examine the uncertainties in the model. Microsoft Excel (version 16.29.1) was used for modeling.

RESULTS : Patients accrued 1.11 more QALYs and cost $32,981 more compared to standard of care of using PD-L1 testing alone. The incremental cost effectiveness ratio of GMT strategy was $75,229 per QALY under base-case assumptions. The 95% credible interval for the ICER was $42,739/QALY to $99,176/QALY. 75.4% of the 10,000-iteration Monte-Carlo probabilistic sensitivity analysis simulations yielded cost-effective results under a $75,000/QALY willingness-to-pay threshold.

CONCLUSIONS : Adding microbiome testing to the routine use of using PD-L1 testing is a cost-effective strategy for guiding treatment of metastatic or unresectable melanoma with willingness-to-pay threshold of $100,000 or above. The addition of GMT may provide economic and clinical value in the care treatment paradigm of metastatic or unresectable melanoma.

Conference/Value in Health Info

2020-05, ISPOR 2020, Orlando, FL, USA

Code

PCN67

Topic

Economic Evaluation, Health Service Delivery & Process of Care, Medical Technologies

Topic Subcategory

Diagnostics & Imaging, Treatment Patterns and Guidelines

Disease

Genetic, Regenerative and Curative Therapies, Oncology, Personalized and Precision Medicine

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×